Screener
Nektar Therapeutics NKTR Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | Fair Value Hierarchy Level | March 31, 2026 / Amortized Cost | March 31, 2026 / Gross Unrealized Gains | March 31, 2026 / Gross Unrealized Losses | March 31, 2026 / Fair Value | December 31, 2025 / Fair Value |
|---|---|---|---|---|---|---|
| Corporate notes and bonds | 2 | $288,887 | $2 | $(723) | $288,166 | $59,785 |
| Corporate commercial paper | 2 | 401,816 | 1 | (307) | 401,510 | 156,714 |
| Obligations of U.S. government agencies | 2 | 4,490 | — | (7) | 4,483 | — |
| Available-for-sale investments | $695,193 | $3 | $(1,037) | $694,159 | $216,499 | |
| Money market funds | 1 | 17,710 | 11,919 | |||
| Certificates of deposit | 2 | 14,029 | 14,138 | |||
| Cash | N/A | 5,699 | 3,196 | |||
| Total cash and investments in marketable securities | $731,597 | $245,752 |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's unrealized gains on investments?
- Nektar Therapeutics (NKTR) reported unrealized gains on investments of $3K in Q1 2026.
Ask your AI about Nektar Therapeutics's unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude